Liposome-encapsulated doxorubicin citrate (Myocet) for treatment of recurrent epithelial ovarian cancer: a retrospective analysis.

Abstract

The aim of this study was to assess the clinical activity and toxicity of liposome-encapsulated doxorubicin citrate (Myocet) in a retrospective multicenter cohort of epithelial ovarian, primary peritoneal, and tubal cancer patients. Records of patients with recurrent epithelial ovarian, primary peritoneal, and tubal cancer treated with liposome-encapsulated doxorubicin citrate (60 mg/m on day 1 of a 21-day cycle) after failure of more than one previous regimen were reviewed. Fifty-three patients were evaluated for efficacy and toxicity. The median age of the patients was 59 (range 39-73). The median follow-up was 6 months (range 1-17). One patient (1.9%) showed a complete response and 13 patients (24.5%) showed a partial response, yielding an overall response rate of 26.4% (14/53 patients). Clinical benefit was achieved in 36 patients (67.9%). The median progression-free survival (PFS) for the entire study population was 4.0 months (range 1.0-14.8). The median PFS for platinum-sensitive and platinum-resistant patients was 4.0 months (ranges 1.0-14.8 and 1.0-9.4, respectively; P=0.652). The median overall survival from the start of liposome-encapsulated doxorubicin citrate was 10.0 months. Multivariate survival analysis showed no association between the liposome-encapsulated doxorubicin citrate line of treatment or platinum sensitivity to PFS in age and BRCA status-adjusted models. Only 11.3% of patients experienced grade 3-4 hematologic toxicities, 80% grade-2 alopecia, and 50% grade-1-2 fatigue. No other grade-4 toxicities, no significant cardiac events, or hand and foot syndromes were reported. Liposome-encapsulated doxorubicin citrate was well tolerated, with a good response and high clinical benefit rate. Further evaluation in a larger prospective cohort is warranted.

• Authors: Ram Eitan, Ami Fishman, Michai Meirovitz, Hadassah Goldenberg, Amnon Amit, Claude Koren, Yulia Schneider, Ora Rosengarten, Avivit Neuman, Shoshanna Keren-Rosenberg, Tamar Safra
• Journal: Anti-cancer drugs (Anticancer Drugs) Vol. 25 Issue 1 Pg. 101-5 (Jan 2014) ISSN: 1473-5741 [Electronic] England
• PMID: 24263191 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Antibiotics, Antineoplastic
• liposomal doxorubicin
• Polyethylene Glycols
• Doxorubicin

Topics

• Adult
• Aged
• Antibiotics, Antineoplastic (administration & dosage, adverse effects, therapeutic use)
• Carcinoma, Ovarian Epithelial
• Doxorubicin (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Female
• Humans
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Neoplasms, Glandular and Epithelial (drug therapy)
• Ovarian Neoplasms (drug therapy)
• Polyethylene Glycols (administration & dosage, adverse effects, therapeutic use)
• Retrospective Studies